Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.

DMARD number, disease duration influence treatment outcomes in rheumatoid arthritis

09 Sep 2019

The previous use of multiple disease-modifying antirheumatic drugs (DMARDs) and disease duration appear to affect treatment outcomes in rheumatoid arthritis (RA) patients initiating adalimumab therapy, according to a posthoc analysis of two randomized controlled trials.

The analysis included 207 patients from DE019 and 67 patients from ARMADA who were treated with adalimumab plus methotrexate (MTX). Treatment response was evaluated at week 24 using the following outcomes: 28-joint Disease Activity Score based on C-reactive protein (DAS28[CRP]), Simplified Disease Activity Index (SDAI), Health Assessment Questionnaire Disability Index (HAQ-DI), and 20%/50%/70% improvement in American College of Rheumatology (ACR) responses.

Disease duration was ≤1 year for nine patients (4.3 percent), >1 to 5 years for 62 (30.0 percent), >5 to 10 years for 43 (20.8 percent) and >10 years for 93 (44.9 percent) in the DE019 cohort; and ≤5 years for 51 patients (76.1 percent) and >5 to 10 years for 16 (23.9 percent) in the ARMADA cohort. With respect to prior use of DMARDs, 75, 62 and 70 patients in DE019 used MTX plus 0–1, 2 and >2 DMARDs, respectively. The corresponding numbers of patients in ARMADA were 41, 13 and 13.

In DE019, a greater number of prior DMARDs (>2 vs 0–1) were linked to nominal improvements in DAS28(CRP) (–1.8 vs –2.2), SDAI (–22.1 vs –26.9) and HAQ-DI (–0.43 vs –0.64) at week 24. RA duration of >10 years vs <1 year was associated with higher HAQ-DI scores (1.1 vs 0.7) at week 24, but results for DAS28(CRP) and SDAI were mixed. A greater number of prior DMARDs and longer RA duration were both associated with lower ACR response rates at week 24.

The findings were consistent in ARMADA.

Taken together, the present data support recommendations to initiate without delay combination therapy with a biologic agent and MTX in patients with inadequate response to MTX monotherapy, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.